Genzyme and Isis Announce that Mipomersen Phase 3 Study Met Primary Endpoint
25 Percent LDL-C Reduction in Very High-Risk Patient Population
26-May-2009 -
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) met its primary endpoint, with a 25 percent reduction in LDL cholesterol after 26 weeks of treatment, vs. 3 percent for placebo ...
cholesterol
homozygous familial hypercholesterolemia
reductions
+1